House, Senate Dems introduce legislation to combat 'abusive' pharma business practices
In the aftermath of Congress introducing legislation allowing Medicare to negotiate drug prices — which currently remains in limbo after the failed passage of the Build Back Better Act — some congressional Dems have shifted gears and have put their targets on other pharma business practices.
House Oversight Committee Chair Carolyn Maloney led a group of Democrat colleagues and introduced three bills on Thursday to target “business practices pharmaceutical companies use to suppress competition, maintain market monopolies, and keep drug prices high,” a statement from the officials said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
